TTR and amyloidosis: Extensive studies on TTR pathophysiology, stability, and aggregation mechanisms resulted in two important therapeutic approaches/treatments against amyloidosis; one approach is directed to the clearance of TTR amyloid burden (siRNA-based, i.e., patisiran and anti-sense oligonucleotide-based therapies, i.e., Tegsedi®), and another approach is focused on TTR stabilization (tafamidis) [21,37,66].